Compare Hut 8 Corp (HUT) vs Novo Nordisk A/S (NVO) Price & Performance

Hut 8 CorpTrade

Novo Nordisk A/STrade

Price performance (Past 24H)

Key statistics

Hut 8 Corp vs Novo Nordisk A/S — how do they compare? Hut 8 Corp trades at $109.49 (market cap $11.36B), while Novo Nordisk A/S trades at $49.35 (market cap $220.53B). The key difference: Novo Nordisk A/S is far larger — about 19.4× Hut 8 Corp's market cap, and Novo Nordisk A/S pays a 3.63% dividend while Hut 8 Corp pays none. Which is the better fit depends on your goals.

	HUT	NVO
Market Cap	$11.36B	$220.53B
Sector	Technology	Health
52-Week High	$133.02	$71.70
52-Week Low	$19.45	$35.29
Enterprise Value	$11.63B	$239.49B
Dividend Yield	—	3.63%

View details →View details →

Returns comparison

Trailing returns across standard periods

Top news

Latest headlines on both assets

HUT

Hut 8 Mining signs $9.8B lease, AMC beats Q2 estimates, Replenish Nutrients secures $15M investmentProactive Investors · 1 day agoBullish Hut 8 signs $9.8B lease to expand AI data center capacity, Needham raises price target to $145Tony Dante · 1 day agoBullish Hut 8 doubles AI data center lease capacity to 704 MW with $9.8B 15-year contract at Beacon Point campusPRNewsWire · 1 day agoBullish View details →

NVO

Novo Nordisk sues Eli Lilly over misleading GLP-1 drug ads claiming superior weight-loss results.Proactive Investors · 9 hours agoBearish Novo Nordisk sues Eli Lilly over misleading ads on obesity and diabetes drug efficacy.CNBC · 13 hours agoBearish Novo Nordisk shares jump 27% on strong sales of oral Wegovy and market expansion.Seeking Alpha · 1 day agoBullish View details →

About Hut 8 Corp

Hut 8 is one of North America's largest digital asset miners and infrastructure providers. It operates diversified data centers supporting Bitcoin mining and high-performance computing (HPC) for AI.

About Novo Nordisk A/S

With almost 50% market share by volume of the global insulin market, Novo Nordisk is the leading provider of diabetes-care products in the world. Based in Denmark, the company manufactures and markets a variety of human and modern insulins, injectable diabetes treatments, and oral antidiabetic agents. Novo also has a biopharmaceutical segment (constituting roughly 15% of revenue) that specializes in protein therapies for hemophilia and other disorders.